LL/2 (LLC1) Mouse Lewis Lung Cancer Cell Line

Introduction

The LL/2 (LLC1) Mouse Lewis Lung Cancer Cell Line was established from the lungs of a C57BL/6 mouse bearing a tumor resulting from the implantation of primary Lewis lung carcinoma. It has been reported that this cell line is resistant to 1, 3-bis-(2-chloroethyl)-1-nitrosourea but sensitive to methotrexate. Studies have shown that LLC cells are highly tumorigenic but exhibit low metastatic potential in mice.

OriCell™ LL/2 (LLC1) Mouse Lewis Lung Cancer Cell Line is commonly used in the research of non-small cell lung cancer (NSCLC).

When citing our products in academic publications, please use the following format: "OriCell™ [Product Name] + [Catalog Number], from Cyagen Biosciences."

Product Information

QC

• Pass the detection of bacteria, fungi, mycoplasma, and endotoxins.
• Verified by cell recovery viability testing.
• Verified by STR analysis.

Please refer to "COA" for details.

General Handling Principles

• Maintain strict aseptic technique. Ensure complete sterility throughout all procedures, particularly within the laminar flow hood and incubator.
• Follow standardized protocols. Adhere strictly to the product manual. Implement rigorous control over experimental variables and include appropriate parallel controls.
• Use high-quality consumables and reagents. This product requires culture vessels suitable for adherent growth, and the reuse of these vessels is not recommended. The reagents used must be validated for reliability, cell compatibility, and batch-to-batch consistency.

Warm Notice: The cryopreservation medium of this product contains DMSO, which may pose potential risks. Please handle it with care.